US equities |
TSLA $395.01 ▲+6.12% MU $904.84 ▲+3.11% SPCX $148.98 ▲+1.01% NVDA $215.37 ▲+2.09% META $642.38 ▼-0.04% AAPL $342.64 ▼-1.46% SNDK $1,256.53 ▲+1.49% INTC $91.03 ▲+4.67%
FinancialContent

Alterity Therapeutics Limited - American Depositary Shares (NQ:ATHE)

2.022 -0.068 (-3.25%)
Delayed Quote Updated: 12:42 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alterity Therapeutics Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Surges 150 Points; US Jobless Claims Decline Sharply ↗
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 150 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.43% to 35,239.40 while the NASDAQ... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Guess? Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket ↗
Shares of Guess?, Inc. (NYSE: GES) shares dipped in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning! 
Via InvestorPlace
News headline image
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
New Patent Covers Over 150 Novel Compounds 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple System Atrophy 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
Wearable sensor parameters correlate strongly with clinical scales of motor impairment 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket ↗
Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday. 
Via Benzinga
News headline image
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity's Parkinson's Candidate Prevents Loss Of Brain Cells In Animal Model ↗
 
Via Benzinga
News headline image
Here's Why Alterity Therapeutics Shares Are Moving ↗
Alterity Therapeutics Ltd (NASDAQ: ATHE) shares are trading higher by 5.67% to $4.12 Monday morning after the company announced ATH434 prevents loss of brain cells in Parkinson's Disease animal model. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >